Viromer® in oncology research

Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. Over 100 type of cancers have been identified to affect humans, causing about 16% of total annual deaths worldwide, with even a higher incidence in developed countries. In the last decades, progress in molecular genetics have permitted to better understand their mechanisms, their origin, and the role played by external factors, enabling the development of targeted therapies and early diagnosis. However, oncology research continues facing numerous challenges and fundamental knowledge is still required to propose innovative therapeutics.

As immortalized and transformed cells, the fate of cancer cells into a defined organ and their potential to spread to other tissues are typically considered in a context of gene regulation. Transfection is therefore a powerful tool to work on these mechanisms by enabling silencing or overexpression of specific genes such as oncogenes or tumor suppressor genes. For all types of cancer cells (carcinoma, sarcoma, glioma, lymphoma), model human and murine cell lines have been established; most of them being suitable as transfection hosts and commercially available. However, despite their high division rate, not all cancer cell lines used in research labs are easy-to-transfect. The Viromer® technology has addressed that challenge through a polymer-based chemistry emulating a viral mechanism.  As detailed in our cell database, about 80 cancer cell types, including primary cells, are amenable to transfection by using the Viromer® reagents.

Expression of GFP in A549 cells transfected with Viromer® RED (after 24h, approx. 80% of transfected cells, no toxicity).

siRNA-mediated gene silencing

Up to 80-100% complete specific gene knock-downs have been achieved by transfecting siRNA into different kinds of cancer cells using Viromer® BLUE  or  Viromer® GREEN:

Protein expression

mRNA versus pDNA

As detailed at the Viromer® in mRNA transfection page, mRNA rather than plasmid transfection can solve difficulties encountered to overexpress proteins in some specific cases. Take some time and go through the cancer cell database below und see, how Viromer can support your research.


Viromer® BLUE | Viromer® GREEN | Viromer® RED | Viromer® YELLOW

transfection efficiency

< 30% | 30-50% | 50-80% | > 80%

Box is empty?! Give it a try and contact our sales team!

Type siRNA mRNA pDNA Data
1321N1      See data
22Rv1     See data
A549              See data Publications
BLM    See data
breast carcinoma cells, primary mouse     See data
BT474          Publications
C6     See data Publication
Ca9-22         See data
Caco-2      See data
Cal-27    See data
Cancer stem cells (3D-mammospheres)     See data
CB committed basal cells, human primary patient-derived prostate epithelial     Publication
CMT-93     Publication
Colon carcinoma cells, primary human       See data
CT-26          See data
cytotrophoblasts, primary human, villous     Publication
Disaggregated xenograft, primary human      See data